U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

On May 14, 2013, the U.S. Food and Drug Administration approved erlotinib (Tarceva, Astellas Pharma Inc., Northbrook, IL, http://www.us.astellas.com/) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR)...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Khozin, Sean, Blumenthal, Gideon M., Jiang, Xiaoping, He, Kun, Boyd, Karen, Murgo, Anthony, Justice, Robert, Keegan, Patricia, Pazdur, Richard
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: AlphaMed Press 2014
Gaiak:
Regulatory Issues: FDA
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4077454/
https://ncbi.nlm.nih.gov/pubmed/24868098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0089
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak